Nektaria Papadopoulou, Jane Wrigley, Andrew McKenzie, Lucy Harris, Jason King, Louise Wainwright, Kelly Jones, Qian Shi, Anne Collins*, and Rajendra Kumari
*University of York, York, UK
Prostate cancer is the second most common cancer worldwide for males, and the fourth most common cancer overall, with more than a million new cases diagnosed annually.
Progress towards understanding prostate cancer biology and developing new therapies has been hampered by a lack of in vivo models that adequately represent the spectrum of benign, latent, aggressive, and metastatic forms of the disease.
Learn about the validation of a panel of preclinical prostate cancer models including cell line models and new patient-derived xenografts (PDX) designed to meet this need.